Who are TAC chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TCH chemotherapy, FLOT, C-BEAM Regimen, dtEC→dtT, AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tac-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TAC chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TAC chemotherapy (TAC chemotherapy) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen (combination). Area: Oncology.

marketed Chemotherapy regimen (combination) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TAC chemotherapy (TAC chemotherapy) — Agendia. TAC is a chemotherapy regimen combining docetaxel, doxorubicin, and cyclophosphamide to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TAC chemotherapy TARGET	TAC chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)
TCH chemotherapy	TCH chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)	HER2, microtubule, DNA
FLOT	FLOT	European Organisation for Research and Treatment of Cancer - EORTC	marketed	Chemotherapy regimen (combination)
C-BEAM Regimen	C-BEAM Regimen	The First Affiliated Hospital with Nanjing Medical University	phase 3	Chemotherapy regimen (combination)
dtEC→dtT	dtEC→dtT	Karolinska University Hospital	phase 3	Chemotherapy regimen (combination)
AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF	AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF	Shandong Cancer Hospital and Institute	phase 3	Chemotherapy regimen (combination)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen (combination) class)

Agendia · 2 drugs in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
Karolinska University Hospital · 1 drug in this class
Shandong Cancer Hospital and Institute · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TAC chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/tac-chemotherapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing